Evidence map›Paper›PMID 33805347›Full record

ArticleMolecules (Basel, Switzerland)2021

5-Aza-2'-Deoxycytidine and Valproic Acid in Combination with CHIR99021 and A83-01 Induce Pluripotency Genes Expression in Human Adult Somatic Cells.

Alain Aguirre-Vázquez, Luis A Salazar-Olivo, Xóchitl Flores-Ponce, Ana L Arriaga-Guerrero, Dariela Garza-Rodríguez, María E Camacho-Moll, Iván Velasco, Fabiola Castorena-Torres, Nidheesh Dadheech, Mario Bermúdez de León

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Alain Aguirre-VázquezCentro de Investigación Biomédica del Noreste, Departamento de Biología Molecular, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León 64720, Mexico.
Luis A Salazar-OlivoDepartamento de Biología Molecular, Instituto Potosino de Investigación Científica y Tecnológica, San Luis Potosí, San Luis Potosí 78216, Mexico.ORCID 0000-0001-6906-4561
Xóchitl Flores-PonceInstituto de Fisiología Celular-Neurociencias, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.
Ana L Arriaga-GuerreroCentro de Investigación Biomédica del Noreste, Departamento de Biología Molecular, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León 64720, Mexico.
Dariela Garza-RodríguezCentro de Investigación Biomédica del Noreste, Departamento de Biología Molecular, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León 64720, Mexico.
María E Camacho-MollCentro de Investigación Biomédica del Noreste, Departamento de Biología Molecular, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León 64720, Mexico.
Iván VelascoInstituto de Fisiología Celular-Neurociencias, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.ORCID 0000-0002-8953-6578
Fabiola Castorena-TorresEscuela de Medicina, Tecnologico de Monterrey, Monterrey, Nuevo León 64710, Mexico.
Nidheesh DadheechClinical Islet Transplant Program, Alberta Diabetes Institute, University of Alberta, Edmonton, AB T6G2E1, Canada.ORCID 0000-0002-7155-0486
Mario Bermúdez de LeónCentro de Investigación Biomédica del Noreste, Departamento de Biología Molecular, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León 64720, Mexico.
Mexican Social Security Institute · MXInstitute for Scientific and Technological Research · MXInstituto Nacional de Neurología y Neurocirugía · MXTecnológico de Monterrey · MXUniversity of Alberta · CA

Funding

Consejo Nacional de Ciencia y Tecnología 271815Instituto Mexicano del Seguro Social FIS/IMSS/PROT/PRIO/16/058
6 · The paper itself

Abstract

A generation of induced pluripotent stem cells (iPSC) by ectopic expression of OCT4, SOX2, KLF4, and c-MYC has established promising opportunities for stem cell research, drug discovery, and disease modeling. While this forced genetic expression represents an advantage, there will always be an issue with genomic instability and transient pluripotency genes reactivation that might preclude their clinical application. During the reprogramming process, a somatic cell must undergo several epigenetic modifications to induce groups of genes capable of reactivating the endogenous pluripotency core. Here, looking to increase the reprograming efficiency in somatic cells, we evaluated the effect of epigenetic molecules 5-aza-2'-deoxycytidine (5AZ) and valproic acid (VPA) and two small molecules reported as reprogramming enhancers, CHIR99021 and A83-01, on the expression of pluripotency genes and the methylation profile of the OCT4 promoter in a human dermal fibroblasts cell strain. The addition of this cocktail to culture medium increased the expression of OCT4, SOX2, and KLF4 expression by 2.1-fold, 8.5-fold, and 2-fold, respectively, with respect to controls; concomitantly, a reduction in methylated CpG sites in OCT4 promoter region was observed. The epigenetic cocktail also induced the expression of the metastasis-associated gene S100A4. However, the epigenetic cocktail did not induce the morphological changes characteristic of the reprogramming process. In summary, 5AZ, VPA, CHIR99021, and A83-01 induced the expression of OCT4 and SOX2, two critical genes for iPSC. Future studies will allow us to precise the mechanisms by which these compounds exert their reprogramming effects.

Indexed as

Cell DifferentiationCell LineDecitabineEpigenesis, GeneticFibroblastsGene ExpressionHumansKruppel-Like Factor 4PyrazolesPyridinesPyrimidinesThiosemicarbazonesValproic AcidA-83-01Chir 99021DecitabineKLF4 protein, humanKruppel-Like Factor 4PyrazolesPyridinesPyrimidinesThiosemicarbazonesValproic Acid5-aza-2′-deoxycytidineepigeneticsreprogrammingstem cellsvalproic acid

Identifiers

PMID33805347
PMCPMC8036574
OpenAlexW3141529164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.